<sup>68</sup>Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U. · 2019

Read <sup>68</sup>Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. by Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6424229.txt.

Description

Giesel and co-authors report early human data on two gallium-68 FAPI tracers used in PET/CT scans of cancer patients, published in 2019. The tracers target fibroblast activation protein, which appears at high levels in the support cells around many tumors. Earlier lab work and a few clinical cases had raised hopes for sharper imaging.

Dosimetry from two patients suggested a 200 MBq scan gives roughly 3 to 4 mSv, close to standard tracers. Scans in 25 patients per tracer showed low uptake in healthy organs after fast kidney clearance. FAPI-4 held in tumors longer than FAPI-2, and both matched FDG on tumor uptake with lower background in brain and liver.

Catalog record

CREATORGiesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6424229

Browse the full library · About the Tower of Babel